Why the study?
Does moxonidine 0.4 mg orally reduce sympathetic nerve activity and blood pressure in healthy volunteers and untreated hypertensives?
Population
33 subjects total: 8 healthy volunteers and 25 untreated hypertensives
Comparison
Moxonidine 0.4 mg orally vs Placebo (for the 25 untreated hypertensives)
Design
RCT, Double-blind, placebo-controlled (for the hypertensive cohort)
Follow-up
24 hours
Authors
Loading...
Supports moxonidine for BP control via sympatholysis in hypertension; confirms central I1-agonist mechanism in human RCT.
Does moxonidine 0.4 mg orally reduce sympathetic nerve activity and blood pressure in healthy volunteers and untreated hypertensives?
Moxonidine effectively lowers blood pressure and sympathetic nerve activity in untreated hypertensives, confirming its central sympatholytic mechanism of action in humans.
Wenzel et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: